This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2012 Feb 21;156(4):317-8.

doi: 10.7326/0003-4819-156-4-201202210-00014.

Hepatitis C: the end of the beginning and possibly the beginning of the end

Harvey J Alter, T Jake Liang

PMID: 22351718
PMCID: PMC3480337
DOI: 10.7326/0003-4819-156-4-201202210-00014

Editorial

Hepatitis C: the end of the beginning and possibly the beginning of the end

Harvey J Alter et al. Ann Intern Med. 2012.

. 2012 Feb 21;156(4):317-8.

doi: 10.7326/0003-4819-156-4-201202210-00014.

Authors

Harvey J Alter, T Jake Liang

PMID: 22351718
PMCID: PMC3480337
DOI: 10.7326/0003-4819-156-4-201202210-00014

No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest: None disclosed. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-0093.

Comment on

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. Rein DB, et al. Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4. Ann Intern Med. 2012. PMID: 22056542 Free PMC article.
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. Liu S, et al. Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005. Ann Intern Med. 2012. PMID: 22351713 Free PMC article.

Similar articles

The cost-effectiveness of birth cohort screening for hepatitis C antibody in US primary care settings.
Vuppalanchi R, Kwo PY. Vuppalanchi R, et al. Gastroenterology. 2013 Feb;144(2):457-459. doi: 10.1053/j.gastro.2012.12.013. Epub 2012 Dec 20. Gastroenterology. 2013. PMID: 23260498 No abstract available.
Clinical practice. Chronic hepatitis C infection.
Rosen HR. Rosen HR. N Engl J Med. 2011 Jun 23;364(25):2429-38. doi: 10.1056/NEJMcp1006613. N Engl J Med. 2011. PMID: 21696309 Review. No abstract available.
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. Liu S, et al. Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005. Ann Intern Med. 2012. PMID: 22351713 Free PMC article.
Antiviral agents and hepatitis C.
Archer-Festa M, Nilsen-Kupsch S. Archer-Festa M, et al. N Y State Dent J. 2012 Jun-Jul;78(4):42-5. N Y State Dent J. 2012. PMID: 23252194
Protease inhibitors for hepatitis C: economic implications.
Turner SJ, Brown J, Paladino JA. Turner SJ, et al. Pharmacoeconomics. 2013 Sep;31(9):739-51. doi: 10.1007/s40273-013-0073-2. Pharmacoeconomics. 2013. PMID: 23839698 Review.

See all similar articles

Cited by

Spatiotemporal Phylodynamics of Hepatitis C Among People Who Inject Drugs in India.
Clipman SJ, Mehta SH, Rodgers MA, Duggal P, Srikrishnan AK, Saravanan S, Balakrishnan P, Vasudevan CK, Ray SC, Kumar MS, Quinn TC, Cloherty GA, Lucas GM, Solomon SS. Clipman SJ, et al. Hepatology. 2021 Oct;74(4):1782-1794. doi: 10.1002/hep.31912. Epub 2021 Aug 25. Hepatology. 2021. PMID: 34008172 Free PMC article.
Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients.
Mantravadi S. Mantravadi S. Health Equity. 2017 Sep 1;1(1):156-164. doi: 10.1089/heq.2017.0018. eCollection 2017. Health Equity. 2017. PMID: 30283843 Free PMC article.
Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries.
Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Kumar A, et al. Indian J Med Res. 2018 May;147(5):445-455. doi: 10.4103/ijmr.IJMR_1850_16. Indian J Med Res. 2018. PMID: 30082568 Free PMC article. Review.
Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis.
Solomon SS, McFall AM, Lucas GM, Srikrishnan AK, Kumar MS, Anand S, Quinn TC, Celentano DD, Mehta SH. Solomon SS, et al. PLoS Med. 2017 Nov 28;14(11):e1002460. doi: 10.1371/journal.pmed.1002460. eCollection 2017 Nov. PLoS Med. 2017. PMID: 29182638 Free PMC article.
Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial.
Salama H, Medhat E, Shaheen M, Zekri AN, Darwish T, Ghoneum M. Salama H, et al. Int J Immunopathol Pharmacol. 2016 Dec;29(4):647-653. doi: 10.1177/0394632016674954. Epub 2016 Oct 31. Int J Immunopathol Pharmacol. 2016. PMID: 27799299 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62. - PubMed
1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494–500. - PubMed
1. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–51. - PubMed
1. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206. - PMC - PubMed
1. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources